Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT03605056Phase 2Unknown
- Start
- Jul 2018
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in multiple myeloma (MM). Primary endpoint: Response Rate at 2 years. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03605056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03605056.